Acura Pharmaceuticals, Inc and King Pharmaceuticals, Inc announced top-line results from Study AP-ADF-111 (Study 111) entitled 'A phase-II, Single-Center, Randomized, Double-Blind, Assessment of the Abuse Liability of Acurox (oxycodone HCl and niacin) tablets in subjects with a History of Opioid Abuse'.
The details can be read here.
No comments:
Post a Comment